Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.1K
Autoimmune Disorders01:29

Autoimmune Disorders

1.9K
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
1.9K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.0K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.0K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial.

Health technology assessment (Winchester, England)·2026
Same author

The clinical, radiological and genetic spectrum AARS2-related leukoencephalopathy: a case series of 15 patients and review of the literature.

Journal of neurology·2026
Same author

An automated quantitative report for multiple sclerosis using only 3D T2-fluid-attenuated inversion recovery MRI.

Neuroradiology·2026
Same author

Multi-arm multi-stage platform trials for neurological disease: accelerating progress.

Lancet (London, England)·2026
Same author

Increased functional network connectivity following cognitive rehabilitation in progressive multiple sclerosis with moderate to severe disabilty: findings from the CogEx study.

Journal of neurology·2026
Same author

Recalibration and external validation of vascular risk calculators for multiple sclerosis: A population-based study using CPRD data in England, 1987-2023.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Premature ventricular complexes.

Clinical medicine (London, England)·2026
Same journal

Heart failure with preserved ejection fraction (HFpEF): diagnosis and management for the general physician.

Clinical medicine (London, England)·2026
Same journal

Trends and Widening Inequities in Cardiovascular-Kidney-Metabolic Involvement in Cardiovascular Mortality: A National Spatiotemporal Analysis, 2014-2023.

Clinical medicine (London, England)·2026
Same journal

Educating current and future healthcare professionals on evidence-based sustainable medicine.

Clinical medicine (London, England)·2026
Same journal

UK Foundation Programme training needs a national minimum standard for advanced life support.

Clinical medicine (London, England)·2026
Same journal

Prognostic value of left atrial diameter in chronic kidney disease: The KNOW-CKD study.

Clinical medicine (London, England)·2026
See all related articles

Related Experiment Video

Updated: Feb 17, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K

Multiple sclerosis, a treatable disease .

Anisha Doshi1, Jeremy Chataway2

  • 1University College London, London, UK anisha.doshi@ucl.ac.uk.

Clinical Medicine (London, England)
|December 3, 2017
PubMed
Summary
This summary is machine-generated.

This review covers multiple sclerosis (MS), a disabling neurological condition. It details MS subtypes, diagnostic criteria, and current treatments, emphasizing the need for better therapies for progressive MS.

Keywords:
Diagnostic criteriaepidemiologymultiple sclerosisprogressive multiple sclerosistreatments

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.7K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.9K

Related Experiment Videos

Last Updated: Feb 17, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.7K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.9K

Area of Science:

  • Neurology
  • Immunology

Background:

  • Multiple sclerosis (MS) is a chronic, disabling neurological disease with significant socioeconomic impact.
  • MS affects the central nervous system, leading to diverse clinical presentations.
  • The exact cause of MS remains unknown, but several factors are associated with its development.

Purpose of the Study:

  • To provide a comprehensive overview of the current understanding of multiple sclerosis.
  • To review modern diagnostic criteria and treatment strategies for MS.
  • To identify gaps in treatment, particularly for progressive forms of MS.

Main Methods:

  • Literature review of current research on multiple sclerosis.
  • Analysis of diagnostic criteria and classification of MS subtypes.
  • Summary of existing and emerging treatment strategies for MS management.

Main Results:

  • Key diagnostic features and major MS subtypes (clinically isolated syndrome, relapsing-remitting MS, secondary progressive MS, primary progressive MS) are described.
  • Current understanding of MS etiology and associated factors is summarized.
  • Treatment approaches for acute relapses, disease-modifying therapies, and symptom management are presented.

Conclusions:

  • Effective management strategies exist for certain MS types, but progressive MS lacks sufficient disease-modifying treatments.
  • Further research and development are crucial to address the unmet needs in progressive multiple sclerosis treatment.
  • This review underscores the importance of continued innovation in MS therapeutics.